Regulation of oncogenic genes by MicroRNAs and pseudogenes in human lung cancer.

Lung cancer is one of the most common mortal cancer types both for men and women. Several different biomarkers have been analyzed to reveal lung cancer prognosis pathways for developing efficient therapeutics and diagnostic agents. microRNAs (miRNAs) and pseudogenes are critical biomarkers in lung cancer and alteration of their expression levels has been identified in each step of lung cancer tumorigenesis.

Therapeutic Targeting of microRNAs in Cancer: Future Perspectives.

Preclinical Research The discovery of microRNAs (miRNAs) and their link with cancer has opened a new era in cancer therapeutics. Approximately, 18 - 24 nucleotides long, miRNAs can up-regulate or down-regulate gene expression in many cancer types and are respectively categorized as oncogenes (oncomirs) or tumor suppressors. Expression profiles of miRNAs with biomarker potential can be used for the classification, diagnosis, therapeutic treatment, and prognosis of different cancer types.

MicroRNAs and cancer; an overview.

MiRNAs are a family of small, endogenous, and evolutionarily conserved non-coding ribonucleic acids that have been involved in the regulation of several essential, cellular, and functional processes. MicroRNAs are known to play key roles in all types of cancer and function as oncogenes (oncomirs) or tumour-suppressors in up-regulation or down-regulation processes respectively. MiRNAs have potential power to be examined as prognostic and diagnostic biomarkers.

Effect on anterior chamber bevacizumab injection combined with seton implantation in treatment of rubeosis iridis in neovascular glaucoma.

Objective: To evaluate the effect of anti-VEGF (bevacizumab) injection to the posterior chamber (BIPC) behind the iris combined with seton implantation in treatment of neovascular glaucoma (NVG).

Methods: Twenty-eight eyes with NVG who underwent BIPC, prospectively evaluated. Anterior segment photographs were taken for grading of neovascularization on anterior segment in pretreatment period and at each follow-up.